Tag: Myositis

Myocarditis, an inflammation of the heart muscle, is the most common and most lethal cardiovascular adverse event linked to immune checkpoint inhibitor (ICI) therapy, with some estimates reporting mortality rates as high as 50%. Understanding what is the most common manifestation of cardiotoxicity associated with immune checkpoint inhibitors is critical for early detection and improving patient outcomes.

Dermatomyositis is a rare autoimmune disease affecting about 10 in every million U.S. residents [1.3.4]. A key question for patients and clinicians is, how does IVIG work in dermatomyositis to combat the characteristic muscle weakness and skin rashes? [1.4.1, 1.4.5]

While fenofibrate is a valuable medication for managing high triglycerides and cholesterol, it is associated with a rare but serious risk of muscle-related side effects, including myositis. Understanding this risk is crucial for patients, especially those on combination therapy with other lipid-lowering drugs.